Cleerly

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Cleerly, Medical and health, 110 16th Street, Suite 1400 #104, Denver, CO.

Cleerly is a comprehensive, AI-driven platform that quantifies and assesses coronary artery disease (CAD) to deliver clinically actionable insights through a web-based solution. Our software quantifies atherosclerosis by measuring plaque volume, composition, length, and location, evaluates stenosis severity in both 2D (diameter and area) and 3D (lumen and vessel volume), with a workflow for determining the likely presence or absence of ischemia, potentially reducing the need for additional testing and enhancing diagnostic confidence.

02/12/2026

Not all plaque carries equal risk.

Hard (calcified) plaque is more stable.
Soft (non-calcified) plaque is dangerous.

Soft, non-calcified plaque is more likely to rupture and more likely to be missed by traditional tests.

Cleerly’s advanced plaque analysis color codes and quantifies all types of coronary plaque from a non-invasive CCTA, giving physicians clarity where traditional methods fall short.

With the new Category I CPT® code and increased insurance coverage, our technology is covered for the majority of insured lives across the United States.

👉 Learn more: https://bit.ly/4rg0frg

02/10/2026

Traditional risk models weren’t built for everyone.

is helping change that.

With ~50% female participation across 12 countries, the study has demonstrated that certain coronary plaque features present a higher risk of MACE in women compared to men, emphasizing the need for tailored preventive strategies for women.

More representative data is how we move from one-size-fits-all risk models to truly equitable cardiovascular care. 💪❤️

📝 Source: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.125.018235

02/06/2026

Team Cleerly is fiRED up to support the American Heart Association's 'Go Red for Women' initiative and bring awareness to heart disease, the #1 killer of women.

On , we’re spotlighting what’s often overlooked:

🟥 Coronary plaque in women

🟥 Underdiagnosis

🟥 Missed risk

When you see more, you can do more. ❤️

Visit goredforwomen.org to learn more!

02/01/2026

❤️ February marks , when the prevention, detection, and care of heart disease steps into the spotlight.

But heart disease isn’t a month-long issue.

According to the CDC, it has remained the leading cause of death in the United States for over 100 years.

While awareness of the most common symptoms and risk factors has improved, heart disease doesn’t always start with symptoms, and physicians' ability to see plaque is the missing piece.

Research shows high-risk soft plaque is the primary driver of disease. However, today’s standard of care often overlooks this silent culprit.

That’s why at Cleerly, Heart Month isn’t just one month; it’s every month.

It’s a philosophy, woven into every conversation and innovation, because creating a new standard of care begins with seeing plaque and understanding risk earlier. 🔍🫀

Source: https://bit.ly/4teVhfU

01/01/2026

✨ Effective today, we're entering a new chapter in heart care coverage.

Cleerly's AI-enabled plaque analysis is now billable under Category I CPT® Code 75577.

Category I designation signals that quantitative plaque assessment is no longer considered experimental; it's a recognized tool that supports doctors in targeting the primary cause of heart disease: plaque buildup in the heart's arteries.

Cleerly helped lead this effort with the American Medical Association over the past five years, and we're excited about what this means for people seeking earlier, clearer answers about their heart health.

Here's to a brighter, healthier 2026! ❤️

12/25/2025

From our hearts to yours, Happy Holidays from team Cleerly!

Wishing you a season full of clarity, connection, and time to focus on what matters most. ❤️

11/06/2025

✨ A truly inspiring night at the 2025 Prix Galien USA Awards in New York City!

We're proud Cleerly was named a finalist for Best Digital Health Solution, and honored to be in great company with so many passionate innovators.

Big thanks to Galien Foundation for this recognition, and congratulations to this year's category winner, ŌURA.

We're so grateful for everyone who supports our mission at Cleerly! Your belief inspires us to keep pushing boundaries.

Looking forward to what's ahead! 🚀❤️

10/31/2025

🎃 Precision meets personality. 👻

Happy from team Cleerly!

09/29/2025

On 🌎❤️, we pause to recognize the millions of lives shaped by heart disease, not as statistics, but as stories, families, and futures.

At Cleerly, we believe in a world where heart attacks can be prevented, where doctors have the clarity to act earlier, and where communities thrive with better access to life-saving care.

This work is not easy, but it's necessary. And we are committed, alongside HCPs, researchers, and advocates worldwide, to creating a new standard of care. One that redefines what it means to protect the heart.

The path forward is bold. The purpose is profound. And our dedication will not waver.

09/19/2025

✨ Wow, simply wow! We're truly honored to be named among TIME's World's Top HealthTech Companies of 2025.

This recognition reflects the urgent need for innovation in cardiology. We're proud to be advancing cardiovascular care with AI, helping physicians make more informed, data-driven decisions for their patients.

👉 Learn more: https://bit.ly/46M2ive

09/15/2025

If warning signs are absent in so many cases, how reliable is a symptom-driven approach to cardiovascular risk? 🤔

For decades, preventive strategies have used cholesterol and other indirect markers to guide clinical decision-making. Yet plaque can often accumulate silently, advancing until it triggers a major adverse cardiovascular event.

If the absence of symptoms does not equal the absence of disease, then it's critical that the disease itself, plaque, comes into clinical view. 🔍🫀

*Cleerly LABS is not a screening tool and should be used only for patients with CAD or suspected of CAD.

09/08/2025

For over a century, heart disease has been the leading killer, yet non-invasive methods for evaluating it primarily rely on indirect markers instead of directly assessing the disease itself. 🤯💔

As a result, plaque buildup (atherosclerosis) in the arteries can progress silently until it causes a Major Adverse Cardiovascular Event (MACE).

At Cleerly, we're committed to changing this trajectory. Our AI-enabled CCTA solution enables physicians to quantify and characterize plaque, providing comprehensive, accurate, and trackable insights to personalize heart attack prevention.

Address

110 16th Street, Suite 1400 #104
Denver, CO
80202

Website

http://www.cleerlyhealth.com/, https://cleerlyhealth.com/indications-for-use

Alerts

Be the first to know and let us send you an email when Cleerly posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cleerly:

Shortcuts

Want your practice to be the top-listed Clinic in Denver?